Development of Monoclonal Antibody-Based EIA for Tetranor-PGDM which Reflects PGD₂ Production in the Body

Figure 1

Optimization of competitive EIA. Effects of pH value (a) and ionic strength (b) on assay buffer on performance of EIA. (c) Inhibition curve for tetranor-PGDM under the optimized conditions. (d) Detection limit and quantitation range for tetranor-PGDM. Arrow : the detection limit; arrow : the lower and upper limits of quantitation range.

(a)

(b)

(c)

(d)